Active Ingredient History

  • Now
Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.   NCATS

  • Mol. Mass: 315.473
  • ALogP: 4.27
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


$1.6940 - $2.8498

United States

$16.2057 - $22.8061
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)- | 2-(n-n-propyl-n-2-thienylethylamino)-5-hydroxytetralin | (+--)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | (6s)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol | ent-rotigotine | leganto | n 0437 | n-0437 | n 0437, hydrochloride, (r)-isomer | n 0437, hydrochloride, (s)-isomer | n 0437, (-)-isomer | n 0437, (+-)-isomer | n 0437, (r)-isomer | n 0923 | n-0923 | n 0924 | n-0924 | neupro | rotigotine | rotigotine, (+--)- | rotigotine cds | spm 962 | spm-962 | (s)-(-)-rotigotine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue